Optical coherence tomography biomarkers as outcome predictors to guide dexamethasone implant use in patients with iERM: a randomized controlled trial
BMC Ophthalmology · 2024
DOI: 10.1186/s12886-024-03429-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BMC Ophthalmology, 2024. Verfasst von Rong Luan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and S…. Hauptthemen laut MEDLINE: Biomarkers, Dexamethasone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Key Medical Discipline ( Specialty ) Construction Project.
Abstract (Originalsprache)
Background
We aimed to investigate the anatomical features of optical coherence tomography (OCT) and vitreous cytokine levels as predictors of outcomes of combined phacovitrectomy with intravitreal dexamethasone (DEX) implants for idiopathic epiretinal membrane (iERM) treatment.
Methods
A prospective, single-masked, randomized, controlled clinical trial included 48 eyes. They were randomly assigned in a 1:1 ratio to undergo the DEX group (combined phacovitrectomy with ERM peeling and Ozurdex implantation) and control group (phacovitrectomy only). Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were assessed at 1 d, 1 week, 1 month, and 3 months. The structural features of OCT before surgery were analysed for stratified analysis. Baseline soluble CD14 (sCD14) and sCD163 levels in the vitreous fluid were measured using ELISA.
Results
BCVA and CMT were not significantly different in the DEX and control groups. Eyes with hyperreflective foci (HRF) at baseline achieved better BCVA ( P time*group =0.746; P group =0.043, Wald χ²=7.869) and lower CMT (Ptime*group = 0.079; Pgroup = 0.001, Wald χ²=6.774) responses to DEX during follow-up. In all patients, the mean vitreous level of sCD163 in eyes with HRF was significantly higher than that in eyes without HRF ( P = 0.036, Z=-2.093) at baseline. In the DEX group, higher sCD163 predicted greater reduction in CMT from baseline to 1 month ( r = 0.470, P = 0.049).
Conclusions
We found that intraoperative DEX implantation did not have beneficial effects on BCVA and CMT over a 3-month period in all patients with iERM, implying that the use of DEX for all iERM is not recommended. In contrast, for those with HRF on OCT responded better to DEX implants at the 3-month follow-up and thier vitreous fluid expressed higher levels of sCD163 at baseline. These data support the hypothesis that DEX implants may be particularly effective in treating cases where ERM is secondary to inflammation.
Trial registration
The trail has been registered at Chinese Clinical Trail Registry( https://www.chictr.org.cn ) on 2021/03/12 (ChiCTR2100044228). And all patients in the article were enrolled after registration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, 384300, T…
Förderung
- Tianjin Key Medical Discipline ( Specialty ) Construction Project
Zitieren
APA
Luan, R., Wang, M., Gong, Y., Liu, B., Huang, X., Wang, J., Sun, S., Zhao, J., Chen, X., Yang, Q., Liu, J., Shao, Y., & Li, X. (2024). Optical coherence tomography biomarkers as outcome predictors to guide dexamethasone implant use in patients with iERM: a randomized controlled trial. BMC Ophthalmology. https://doi.org/10.1186/s12886-024-03429-2
Vancouver
Luan R, Wang M, Gong Y, Liu B, Huang X, Wang J, et al. Optical coherence tomography biomarkers as outcome predictors to guide dexamethasone implant use in patients with iERM: a randomized controlled trial. BMC Ophthalmology. 2024. doi:10.1186/s12886-024-03429-2
BibTeX
@article{Luan2024,
author = {Luan, Rong and Wang, Manqiao and Gong, Yi and Liu, Boshi and Huang, Xinyuan and Wang, Jie and Sun, Shuo and Zhao, Jinzhi and Chen, Xiteng and Yang, Qianhui and Liu, Juping and Shao, Yan and Li, Xiaorong},
title = {Optical coherence tomography biomarkers as outcome predictors to guide dexamethasone implant use in patients with iERM: a randomized controlled trial},
journal = {BMC Ophthalmology},
year = {2024},
doi = {10.1186/s12886-024-03429-2}
}
EUVIMED